Genetics of Anthracycline-Associated Cardiotoxicity
Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.867873/full |
| _version_ | 1818060668662710272 |
|---|---|
| author | Talal Khalid Al-Otaibi Benjamin Weitzman Usman A. Tahir Aarti Asnani |
| author_facet | Talal Khalid Al-Otaibi Benjamin Weitzman Usman A. Tahir Aarti Asnani |
| author_sort | Talal Khalid Al-Otaibi |
| collection | DOAJ |
| description | Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated with increased risk of ACT has the potential for significant clinical impact to improve patient care. The goal of this review is to summarize the current evidence supporting genetic variants associated with ACT, identify gaps and limitations in current knowledge, and propose future directions for incorporating genetics into clinical practice for patients treated with anthracyclines. We will discuss mechanisms of ACT that could be illuminated by genetics and discuss clinical applications for the cardiologist/cardio-oncologist. |
| first_indexed | 2024-12-10T13:36:05Z |
| format | Article |
| id | doaj.art-92669010ad3441cda8a7c88f6404d017 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-10T13:36:05Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-92669010ad3441cda8a7c88f6404d0172022-12-22T01:46:49ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-04-01910.3389/fcvm.2022.867873867873Genetics of Anthracycline-Associated CardiotoxicityTalal Khalid Al-OtaibiBenjamin WeitzmanUsman A. TahirAarti AsnaniAnthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated with increased risk of ACT has the potential for significant clinical impact to improve patient care. The goal of this review is to summarize the current evidence supporting genetic variants associated with ACT, identify gaps and limitations in current knowledge, and propose future directions for incorporating genetics into clinical practice for patients treated with anthracyclines. We will discuss mechanisms of ACT that could be illuminated by genetics and discuss clinical applications for the cardiologist/cardio-oncologist.https://www.frontiersin.org/articles/10.3389/fcvm.2022.867873/fullanthracycline associated cardiotoxicitygeneticsgenetic testingcardio-oncologyanthracycline |
| spellingShingle | Talal Khalid Al-Otaibi Benjamin Weitzman Usman A. Tahir Aarti Asnani Genetics of Anthracycline-Associated Cardiotoxicity Frontiers in Cardiovascular Medicine anthracycline associated cardiotoxicity genetics genetic testing cardio-oncology anthracycline |
| title | Genetics of Anthracycline-Associated Cardiotoxicity |
| title_full | Genetics of Anthracycline-Associated Cardiotoxicity |
| title_fullStr | Genetics of Anthracycline-Associated Cardiotoxicity |
| title_full_unstemmed | Genetics of Anthracycline-Associated Cardiotoxicity |
| title_short | Genetics of Anthracycline-Associated Cardiotoxicity |
| title_sort | genetics of anthracycline associated cardiotoxicity |
| topic | anthracycline associated cardiotoxicity genetics genetic testing cardio-oncology anthracycline |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.867873/full |
| work_keys_str_mv | AT talalkhalidalotaibi geneticsofanthracyclineassociatedcardiotoxicity AT benjaminweitzman geneticsofanthracyclineassociatedcardiotoxicity AT usmanatahir geneticsofanthracyclineassociatedcardiotoxicity AT aartiasnani geneticsofanthracyclineassociatedcardiotoxicity |